BiotechTube

Pasireotide + Cabergoline + Pasireotide LAR

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Cushing's Disease

Conditions

Cushing's Disease, Acromegaly, Neuroendocrine Tumors, Pituitary Tumors, Ectopic ACTH Secreting (EAS) Tumors, Dumping Syndrome, Prostate Cancer, Melanoma Negative for bRAF, Melanoma Negative for nRAS

Trial Timeline

Jun 10, 2013 → Jul 25, 2023

NCT ID
NCT01794793

About Pasireotide + Cabergoline + Pasireotide LAR

Pasireotide + Cabergoline + Pasireotide LAR is a approved stage product being developed by Recordati for Cushing's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01794793. Target conditions include Cushing's Disease, Acromegaly, Neuroendocrine Tumors.

What happened to similar drugs?

1 of 9 similar drugs in Cushing's Disease were approved

Approved (1) Terminated (1) Active (7)
✅Pasireotide s.c. + Sitagliptin + Liraglutide + Insulin + Pasireotide LAR + MetforminNovartisApproved
🔄pasireotide LAR + SOM230 LAR 30 mg + SOM230 LAR 10 mgNovartisPhase 3
🔄Pasireotide sub-cutaneousNovartisPhase 3
🔄osilodrostat + osilodrostat PlaceboNovartisPhase 3
🔄PasireotideNovartisPhase 3
🔄mifepristoneCorcept TherapeuticsPhase 3
🔄MifepristoneCorcept TherapeuticsPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01794793ApprovedCompleted

Competing Products

18 competing products in Cushing's Disease

See all competitors
ProductCompanyStageHype Score
AZD4017 and prednisolone + Placebo Oral Tablet and prednisoloneAstraZenecaPhase 2
35
pasireotide LAR + SOM230 LAR 30 mg + SOM230 LAR 10 mgNovartisPhase 3
40
Pasireotide sub-cutaneousNovartisPhase 3
40
osilodrostat + osilodrostat PlaceboNovartisPhase 3
40
OsilodrostatNovartisPhase 2
35
PasireotideNovartisPhase 3
40
Pasireotide s.c. + Sitagliptin + Liraglutide + Insulin + Pasireotide LAR + MetforminNovartisApproved
43
SOM230 s.c.NovartisPhase 2
35
Lu AG13909LundbeckPhase 2
39
OsilodrostatRecordatiPre-clinical
23
osilodrostatRecordatiPhase 2
32
OsilodrostatRecordatiPre-clinical
27
mifepristoneCorcept TherapeuticsPhase 3
37
CORT125134Corcept TherapeuticsPhase 2
32
Cushing's syndrome confirmationCorcept TherapeuticsPre-clinical
15
MifepristoneCorcept TherapeuticsPhase 3
37
mifepristoneCorcept TherapeuticsPhase 3
37
mifepristoneCorcept TherapeuticsPhase 3
29